



September 30, 2018

Management's Discussion and Analysis

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Table of Contents

President's Message	3
Business Overview	4
The Industry	6
NexgenRx Strategy.....	7
NexgenRx Advantage.....	7
Risks and Uncertainties	8
Results of Operations	11
Outstanding Share Data	13
Liquidity and Capital Resources	13
Financial Instruments and Other Instruments.....	13
Plan Sponsor Funds on Deposit Arrangements	13
Critical Accounting Estimates	14
Significant accounting judgments and estimation uncertainties	14
Property and equipment – estimated useful lives.....	14
Valuation of stock based compensation and warrants issued.....	14
Additional information	14

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

President's Message

Dear Shareholders,

The third quarter was a very positive and active quarter for the Company. In addition to the closing of the acquisitions of Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT") we have received approvals on new client implementations that will improve financial results.

As to Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT") their results for the period from August 15th to September 30th have been consolidated into our third quarter results. Their results have contributed positively to the Company. CBA is a Third Party Administrator ("TPA") providing administrative services to plan advisors and other intermediaries who wish to provide their clients with eligibility, enrolment & billing functionality, independent of any one insurance carrier. MyBenetech provides a wholesale value-add SaaS (Software as a Service) platform to plan sponsors who have their own dedicated administrators.

Our revenue for the three month period ending September 30, 2018 grew by 11.7% over the same three month period last year which is a direct result of the acquisitions of CBA/MBT. Revenue for the three month period ending September 30, 2018 was \$1,563,141 (2017: \$1,399,179) and \$4,666,156 (2017: \$4,341,272) year to date. While we incurred a loss the results were impacted by costs associated with the acquisition and client growth initiatives. With the acquisition and new client implementations financial results will improve in the upcoming quarters.

Product Development

We recently completed our web portal technology initiatives and began amortizing the costs. The result is that users of all web-browsers have easy and seamless compatibility with our member-based interactive websites. In addition the plan member experience continues to evolve through our full mobile technology, "**neXmobile®**" iPhone and Android mobile app. Making plan member utilization of services and claims process quicker has continued to improve given we continued to rapidly enroll more targeted healthcare providers to submit claims via our proprietary secure web-portal, **theclaimsXchange.com**. Over the next several quarters new technology projects will be built with customer funded assistance

Looking Forward

We have a solid pipeline of prospects and opportunities. Conversion of these opportunities into clients will provide meaningful revenue to the Company. Our technology-driven offering is recognized as a differentiator for customers seeking more cost effective solutions for their drug, extended health and dental benefits programs. NexgenRx is the only independent full service claims adjudicator with full front end administration capability. This capability allows NexgenRx to provide solutions to segments of our defined market that need sophisticated health benefit technology applications, in a cost-effective manner. NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and deliver superior administration and claims processing solutions at a competitive cost.

NexgenRx is well positioned to capitalize on the market's demand for an alternative to the traditional group benefits offerings and we look forward to the sustained growth of our business during 2018.

As always, thanks to our Customers, staff, Board members and Shareholders for your continued loyalty, support and confidence in NexgenRx.

Sincerely,

Ronald C. Loucks
President and CEO

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Management's Discussion and Analysis

This Management's Discussion and Analysis ("MD&A") of NexgenRx Inc. (the "Company" or "NexgenRx") has been prepared by management as of November 21, 2018. The Company's consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") on a going-concern basis and do not include any adjustments to the amounts and classifications that might be necessary should the Company be unable to continue business.

This MD&A may contain forward-looking statements in respect of various matters, including upcoming events. The results or events predicted in these forward-looking statements may differ materially from actual results or events. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or other factors.

The financial statements and related notes, and this MD&A have been reviewed by the Company's Audit Committee and approved by the Company's Board of Directors.

Business Overview

Further to our press release of July 24th, 2018 the acquisitions of Ontario based privately owned Canadian Benefit Administrators ("CBA") and My Benetech Inc. ("MBT") were closed on August 15th 2018. The purchase price of \$4,000,000 was settled with \$2,800,000 paid upon closing with the balance of \$1,200,000 due on the second anniversary of the closing date, subject to certain standard purchase price adjustments and subject to acceleration of payment in the event of a change of control. The amount paid on the closing date consisted of a cash payment of \$2,650,000 cash, together with an aggregate of \$150,000 in common shares of the Company. An aggregate of 600,000 common shares were issued to the vendors (and allocated among them on a pro rata basis) on the closing date at a price of \$0.25 per share. The remaining balance is due two years from date of closing and will also be guaranteed by CBA and MBT. In addition, of the remaining balance, \$1,100,000 will be paid in cash (subject to adjustments), with the remaining \$100,000 in consideration being issued in the form of shares at a price based upon the ten (10) day average closing price on the two year anniversary of closing (or earlier, in the event of acceleration upon a change of control). The remaining cash portion is subject to a purchase price adjustment in certain circumstances, such as failure to meet earnings and working capital targets. Financing for the cash portion of the purchase price was arranged by way of a secured loan from an arm's length shareholder in the aggregate amount of \$1,750,000, which has been fully funded. The loan bears interest at a rate of four percent (4%) per annum and matures on the date that is one (1) year, plus one (1) day from the date of issuance.

The principals of each of the acquired companies have entered into long-term employment agreements and were granted an aggregate of 500,000 options to acquire common shares in the capital of NexgenRx at a price of \$0.25 for a period of 10 years (vesting as to 33.3% each year for three years, beginning on the first anniversary of the grant date). All of such options (and the common shares issuable upon exercise) will be subject to applicable securities law hold periods.

Acquisition Update

As we've noted above NexgenRx Inc completed the acquisition of two benefits administration companies, Canadian Benefit Administrators Ltd. ("CBA") and My Benetech Inc. ("MBT") on August 15, 2018. CBA is a Third Party Administrator ("TPA") providing administrative services to plan advisors and other intermediaries who wish to provide their clients with eligibility, enrolment & billing functionality, independent of any one insurance carrier. CBA has a team of administrators providing this service on behalf of various plan sponsors. MyBenetech provides a wholesale value-add SaaS (Software as a Service) platform to plan sponsors who have their own dedicated administrators wishing to have the

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

independence from any one insurance carrier, as well as TPA's like NexgenRx. Both organizations use the industry-leading "Vital Objects" software, as the software platform.

The acquisition was recorded as follows;

My Benetech Inc

Fair Value of Identifiable Net Assets	\$
Cash and cash equivalents	285,341
Accounts receivable, other	31,701
Property and equipment	4,884
Intangibles, IP software license	740,000
Intangibles - Customer relationships	280,000
Trade payables, notes payable, client funds	<u>(219,948)</u>
Net assets acquired	<u>1,121,978</u>
Consideration paid	
Cash	1,060,000
Shares issued	60,000
Note payable - cash portion	423,500
Note payable - share portion	<u>40,000</u>
Total consideration paid	<u>1,583,500</u>
Total goodwill	<u>461,522</u>

Canadian Benefit Administrators Ltd

Fair Value of Identifiable Net Assets	\$
Cash and cash equivalents	5,640,941
Accounts receivable, other	54,466
Property and equipment	22,180
Intangibles, IP software licence	1,400,000
Intangibles - Customer relationships	820,000
Trade payables, notes payable, client funds	<u>(5,648,698)</u>
Net assets acquired	<u>2,288,889</u>
Consideration paid	
Cash	1,590,000
Shares issued	90,000
Note payable - cash portion	635,250
Note payable - share portion	<u>60,000</u>
Total consideration paid	<u>2,375,250</u>
Total goodwill	<u>86,361</u>

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Current operations

The Company earns revenue on the sale of its administration and health benefit claims adjudication services to various organizations who manage health benefit plans on behalf of a number of plan sponsors (employers, associations, etc.) and to a lesser extent, directly to large Canadian plan sponsors who wish to provide an Administrative Services Only (“ASO”) health benefit plan to their plan members. Health benefit claims include drug, dental, extended health and health care spending account claims. This service is sold on a fee-per-transaction basis, in addition to per member administration fees.

The Company’s revenue from administration and transaction fees is directly linked to the number of plan members whose health claim benefits are adjudicated and paid by the Company. NexgenRx provides claims adjudication services covering three major benefit classes; drug, dental and extended health care, plus a healthcare spending account. A client may select any combination of these as part of their benefit plan.

Contracts with plan sponsors can extend over several years, and are reviewed by management prior to renewal for any plan design or pricing changes. Plan sponsors can terminate contracts after a specified notice period ranging from one to six months. The Company does not anticipate that it will experience any material bad debts on any termination, as it collects the funds required in advance of processing any claims for a particular plan sponsor. The Company has no obligation to pay any claim on behalf of a plan sponsor should it have insufficient funds on hand from that plan sponsor. All such funds received are held by the Company in a segregated restricted funds on deposit account. Funds are maintained in this account, until paid out on account for claims made under the relevant health benefit plan, fee revenue due to the Company or other authorized disbursements.

The Industry

The Canadian group health benefit market is dominated by a relatively small number of federally incorporated and regulated insurance companies. These insurers are the only providers of certain insurance products (including life insurance, disability insurance, accidental death and dismemberment insurance and/or out of province travel medical emergency insurance) that comprise a significant portion of all health benefit plans. Over time, these companies have extended their product offering into the provision of drug, dental and extended health care benefits and the administration of health benefit plans on both an insured and an ASO basis.

Although some insurers have the technology to enable them to receive and adjudicate both paper and electronic claims made under the health benefit plans managed by them, most insurers (including each of the five largest insurers in Canada) have further outsourced the adjudication of electronic claims, or pay direct card claims, to third party electronic transaction companies.

Intermediaries such as employee benefit consultants and brokers are principally responsible for the design and placement of health benefit plan coverage. Due to their expert knowledge, plan sponsors value and, generally, follow their advice in respect of benefit matters. These intermediaries typically seek out price quotes for various benefit products on an annual basis and make recommendations to their plan sponsor clients.

Distribution to large Canadian groups (over 500 plan members) is dominated by the major consulting firms, most of which are subsidiaries of United States based firms where cost containment is the dominant theme. These firms tend to operate on a national basis with offices in most major Canadian cities and follow standards set by national practice leaders within each firm.

Management believes that small and medium sized employers (10 to 500 employees/members) are more likely to deal with independent brokers that sell across all insurance lines, including health benefits.

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

These brokerages range from one-person shops to significant regional operations. Certain insurance companies have sought to bypass the brokers and seek a direct relationship with plan sponsors.

A trend that started with union trustee plans and now extends to traditional employer plans is the role of a Third-Party Administrator. By retaining a Third-Party Administrator, plan sponsors are able to control their own employee or member data independent of any one insurance company. This allows for the use of multiple carriers to provide a group benefits plan. An employer can utilize the best carrier for the life insurance component, for example, while utilizing a specialty carrier for other insurance coverage. Use of a Third-Party Administrator also enables the employer to find the best provider of health benefit administration services, such as NexgenRx, since the Third-Party Administrator handles all the back-office administration including enrolment data and premium allocation. Third Party Administrators give greater flexibility to employers in this consolidated carrier market and their use is well suited to the carve-out of health and dental coverage.

NexgenRx Strategy

NexgenRx with its technology based platform provides leading administration, claims adjudication and web based solutions to effectively manage benefit costs from plan sponsors and their members. The Company's immediate and long-term objective is to capitalize on its scalable infrastructure by offering cost effective solutions. The infrastructure is capable of handling significant volume increases. The objective is to increase the number of plan members under administration and the volume of health care claims adjudicated by the Company through various distribution channels. Significant growth in volume can be achieved while maintaining a transactions fee price structure that provides a competitively priced offering and an adequate gross margin contribution.

NexgenRx Advantage

Management believes that the Company has a number of significant competitive advantages that will help it to achieve its strategic goals. These advantages include:

- (i) *Pricing* – Compared to a traditional insured benefit model, the Company provides a significant cost advantage for Plan Sponsors.
- (ii) *Technology* – The Company utilizes Adjudication Software which allows complex plan designs to be set up to automatically adjudicate drug, dental and extended health care claims on a single software platform. This is advantageous in the health benefits management industry where health benefit plan designs are becoming increasingly complex and manual adjudication is not uncommon. Most insurers in Canada use a different adjudication platform for health benefit claims received electronically than they do for health benefit claims received in paper form. The Company uses the same Adjudication Software for both types of health benefit claims and offers real-time services such as the electronic adjudication of health care claims made under an integrated health care spending account, cross benefit deductibles (where one deductible may apply to both drug and dental benefits) and yearly or per visit maximums. The service also includes the proactive intervention tools comprising the NexgenRx Intervention Suite;
- (iii) *Flexibility* – The Company is able to adapt to new business methods, different adjudication philosophies, and unique support requirements as a result of its rules-based adjudication engine and experienced and dedicated professional staff. Each client receives dedicated support from the conversion planning stage through to the renewal process, ensuring a personal experience that meets that client's particular business needs; and
- (iv) *Control* – The Company recognized the need in the marketplace to enable traditional group plan sponsors to have control of their own administration without having to disrupt their existing broker/consultant relationship. NexAdmin® responds to that need. By allowing traditional plan

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

sponsors to utilize our web-based application. The ability to offer self-administered enrolment, eligibility and billing changes to interface with a variety of group carriers for their insured benefits such as Life, AD&D, and LTD and still take advantage of the transaction based health and dental benefits administered by NexgenRx. This streamlines the process for dealing with employee eligibility, salary or dependent status changes in a cost effective manner, independent of any one insurer. The ability of a plan sponsor to control their own eligibility and billing data is the key to having the most competitive pricing and design opportunities at all times.

- (v) *Conversion Experience* – The Company is skilled in converting benefit plans and their members from an existing Third Party Administrators' manual or computer system to the the Company's systems. It is critical that changeovers have minimal impact upon plan members. Conversion utilities for eligibility and claims history have been built, template project plans have been written and testing methods and structure have been created;

Risks and Uncertainties

Market Demand

The Health Benefit Management industry is highly competitive and is characterized by changing technology in both products and delivery and by competitive pricing. The Company competes with a number of established companies which enjoy significant market share in segments of the Health Benefit Management market. In order to maintain and improve its position in the industry, the Company must continue to develop its software technology, enhance its current products and services, and develop or acquire new products and product extensions.

Technology Development

The Company's success is dependent on the continued development and enhancement of the Adjudication Software and the Company's other proprietary software technologies. The Company primarily relies on a combination of trade secret, copyright and trademark laws, non-disclosure agreements and contractual provisions to establish and protect its proprietary rights to its products.

Service Providers

The health care claims received by the Company electronically are transmitted over dedicated networks. Such transmission may be interrupted as a result of cable damage or other cause. Based upon management's experience and the service standards which the principal network provider strives to maintain, management anticipates that any such interruption will not often occur or last for any material length of time. However, there can be no assurance that this will be the case, or that any such interruptions, if frequent and prolonged, would not have a material adverse effect on the Company's business. The Company is similarly dependent upon third parties, known and unknown, for the maintenance of the interconnectivity of the Internet. A loss of Internet connectivity would adversely affect, or preclude, plan sponsor and TPA customers of the Company, plan members, health care providers and others from accessing the services which the Company intends to deliver to each of these persons through its website and would interrupt the receipt and transmission of electronic mail, among other consequences. Management does not anticipate that any such loss of Internet connectivity would have a material adverse effect upon its business, but there can be no assurance that this would be the case.

Cyber Security

Cyber security risk is a high priority area of the company given the core of the company's business involves sensitive personal information, such as medical records, that is electronically transmitted over dedicated networks, as noted above. By the nature of the company's business, personal medical and other information is maintained and subject to electronic data exchange. If the company's data were to be

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

comprised the company could face serious reputational damage, loss of customer confidence and potentially impact future opportunities.

The Company recognizes that cybersecurity is an ever-changing environment and that constant monitoring and diligence are required to keep up with day-to-day threats and ever-changing technologies. The Company has contracted an outside cybersecurity firm to assist with protecting both systems and data from cybersecurity attacks. Using patented technology, constant scanning and monitoring of all servers and firewall traffic are done. This technology hardware/software alerts both the cyber security firm and the Company of any vulnerabilities or attacks along with action items and solutions. The Company also recognizes that a significant risk for cybersecurity breach is that of Company employees. Email phishing, spam and pharming are the largest threats to the Company.

The Company also recognizes other threats such as social engineering and malware/viruses or other cybersecurity attacks to be aware of. To mitigate any possible threat posed by Company employees, the Company is constantly training and informing employees about cybersecurity safe practices and conducting training and awareness meeting that employees must attend. Should there ever be a cybersecurity breach at the Company, a cybersecurity incident response plan has been developed. This plan is revised quarterly and all participants of the plan must attend quarterly walk-throughs.

To mitigate this risk, the company has a dedicated technical team that has implemented preventative measures and monitors cyber risks continuously. Testing against cyber risk is also carried out regularly to ensure the potential threat is as low as possible.

Revenue Concentration

For the period ended September 30, 2018, 61% of the company's revenue was derived from three clients (2017 - 69%). The loss of any one of these clients could have a significant impact on the company's future revenue. At the same time, it should be noted that the scalar nature of the infrastructure architecture and the organization design provide significant mitigation against this risk. In addition with the acquisitions revenue concentration will continue to decline.

Market conditions are extremely competitive, and every client is a potential target. Stop-loss experience is constantly under attack as more high cost drugs are coming to market and negatively affecting claims experience and the cost of insuring that risk. As we noted, the industry is dominated by large insurers that can quote predatory pricing. Our competitive strengths include, but is not limited to, responsiveness, dedicated customer relation staff, flexible structuring of offerings, ability to react and accommodate specific needs very quickly, customize our systems to meet client needs to name a few.

To reduce this risk and exposure the Company has, and continues to make, a concerted effort to add new customers. The goal is to reduce exposure to any one client, develop new revenue channels, increase revenues in all areas, but in particular, to add and increase ancillary product offerings. Increasing the number of clients will reduce concentration risks as well. Progress has been made by targeting higher potential client wins and persistently marketing and quoting on prospective clients that seek our offering. With the acquisition and new client implementations the results of our efforts will begin to materialize in the upcoming quarters.

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Summary of Selected Quarterly Information

Prepared in accordance with IFRS

	Q1, 2018	Q2, 2018	Q3, 2018	
	\$	\$	\$	\$
Total revenue	1,545,558	1,464,698	1,655,900	
Net income	(150,525)	(326,722)	(403,662)	
Basic income per common share	(0.002)	(0.005)	(0.006)	
Total assets	9,567,519	8,731,084	19,893,501	
Total liabilities	7,726,198	7,188,529	18,149,629	
Shareholders' equity / (deficiency)	1,841,321	1,542,555	1,743,872	

	Q1, 2017	Q2, 2017	Q3, 2017	Q4, 2017
	\$	\$	\$	\$
Total revenue	1,504,926	1,437,166	1,399,179	1,330,279
Net income	17,042	(109,455)	(151,685)	(381,809)
Basic income per common share	0.000	(0.002)	(0.003)	(0.005)
Total assets	8,563,160	8,922,183	9,052,077	9,668,195
Total liabilities	7,762,330	8,169,828	8,450,102	7,706,103
Shareholders' equity / (deficiency)	800,830	752,355	601,975	1,962,092

	Q1, 2016	Q2, 2016	Q3, 2016	Q4, 2016
	\$	\$	\$	\$
Total revenue	1,411,929	1,565,891	1,397,440	1,379,476
Net income	47,843	89,363	28,657	421,941
Basic income per common share	0.001	0.002	0.000	0.007
Total assets	7,681,593	8,082,699	8,301,531	8,185,283
Total liabilities	7,712,599	8,020,892	8,207,618	7,427,227
Shareholders' equity / (deficiency)	(31,006)	61,807	93,913	758,056

Total Assets / Liabilities

There were no transactions outside of normal operations. Client deposits fluctuate on claims experience with the result being our deposit levels dropped. Cash balances dropped from a combination of a reduction of payables, loans and operating losses in the quarter.

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Results of Operations

For the nine months ended September 30, 2018 revenue grew by \$232,125 or 5.35% vs. the comparable nine months ending September 30, 2017. The number of plan sponsor members was relatively unchanged during the reporting periods. Gross profit margins in the comparative three month rose given there was no incremental cost of sales from CBA and MB. On a year over comparison the gross margin percentage was up slightly for the same reason. For the three months ended September 30, 2018 revenue grew by \$256,721 or 18.35% vs. the comparable three months ending September 30, 2017 with the major contributing factor being the acquisition of CBA and MBT. Operating expenses for the three month period ending September 30, 2018 increased by approximately \$515,000 over the prior year comparable period primarily from operating costs of CBA and MB. Non-recurring acquisition related expenses totaled approximately \$117,500 and are reflected in the three-month period ending September 30, 2018.

The Company, as noted, has won new business. With a solid pipeline of prospects we are optimistic our recent successes can be built upon. As noted in the past, conversion of prospects is always unpredictable and a lengthy process. On the balance sheet, as noted above, cash balances decreased from year end, due to operating losses, the timing of working capital changes and continued investment in our technology. A private placement at \$0.25 per share was completed October 11th, 2018 in the amount of \$425,000 for working capital needs.

Below is a summary of our revenues for the three month period ending September 30. Revenue consists primarily of fees per health benefit claim transaction adjudicated. The Company adjudicates both electronic and paper-based health benefit claims and charges transaction fees per contract with each plan sponsor or TPA. In addition, with the concurrence of its plan sponsor and TPA customers, the Company is entitled to retain the interest earned on the timing difference of funds deposited with the Company in advance of the payment of adjudicated claims to health care providers or to plan members.

	Three months ended September 30, 2018	Three months ended September 30, 2017	Dollar change	%age change
Revenues	\$	\$		
Transaction Fees	1,032,913	1,038,276	(5,363)	-0.52%
Administration Fees	555,904	295,281	260,623	88.26%
Commission	29,301	31,609	(2,308)	-7.30%
Consulting	12,570	21,997	(9,427)	-42.86%
Other Income	25,212	12,016	13,196	109.82%
	1,655,900	1,399,179	256,721	18.35%
	Nine months ended September 30, 2018	Nine months ended September 30, 2017	Dollar change	%age change
Revenues	\$	\$		
Transaction Fees	3,271,792	3,257,087	14,705	0.45%
Administration Fees	1,102,992	912,004	190,988	20.94%
Commission	92,375	92,288	87	0.09%
Consulting	140,671	56,616	84,055	148.47%
Other Income	58,326	23,277	35,049	150.57%
	4,666,156	4,341,272	324,884	7.48%

Transaction fees consist primarily of fees per health benefit claim transaction adjudicated. Transaction fee revenue is recognized on the Company's completion of the adjudication process when it is probable that

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

the economic benefits associated with the transaction will flow to the Company, the amount of revenue can be measured reliably, the stage of completion of the transaction at the end of the reporting period can be measured reliably and the transaction costs incurred to complete the transaction can be measured reliably. These criteria are generally met on completion of the adjudication process. Most of the transaction fees are charged on all claims processed, regardless of the outcome of the adjudication process (i.e. whether the actual claim is approved or declined).

Administration and other fees are the fees charged to provide the initial enrolment, ongoing eligibility tracking, monthly billing services and contract windups. Administration fees are charged to customers based on the actual number of members per month as at the first of the month according to the rates specified in each customer agreement. For the three months ended September 30, 2018 administration fees were higher in 2018 vs. 2017 due to the revenue from acquisition. The number of members in our plan sponsors remained stable over the comparable periods

Commissions are earned from the sale of third party insured products to customers. Consulting revenues are derived from contracted technological changes from our client base which can significantly vary from year to year. The Company has the opportunity to grow its consulting and commission revenues as it brings on new customers. During the three months period ending September 30, the company earned interest of \$25,212 (2017 - \$7,516) on its funds on deposit and is recorded in Other Income. Other income also includes revenues generated from other products not classified in other categories, such as specialty cards and client requests. This other income category is expected to re-occur, however, we note this revenue is client specific and highly variable.

Cost of sales consist of communication costs for the delivery of electronic claims from the health care provider to the Company, the costs related to the off-site hosting of the Company's adjudication computer hardware and related technology support, the cost of adjudication and administration software development and maintenance and commissions related to revenue generation.

Cost of sales of \$252,080 (2017 - \$265,989) for the period was \$13,909 lower compared with the same period in the prior year. This is reflective of the slight decrease in associated direct costs.

	Three months ended	Three months ended	Dollar
	September 30, 2018	September 30, 2017	change
Expenses			
Compensation and external contractors	1,274,359	940,211	334,148
General and administrative / other	533,123	344,664	188,459
Total	1,807,482	1,284,875	522,607

Overall quarterly expenses of \$1,807,482 (2017 - \$1,284,875) increased by \$522,607 compared to the prior year quarter. The increase in compensation / external contractors was due to increased staffing in the sales / customer service area, additional contractors and acquisition related costs. Independent contractors are used for specialist roles and provides the company with flexible costing. Compensation costs also include compensation expenses of \$146,733 of the acquired companies. Of the \$181,089 increase in general and administrative, \$106,891 is non-cash related to the amortization of intangibles and stock option expense. The remaining increase \$74,198 in costs were driven primarily by the professional fees associated with the acquisition and increased marketing expenses. There were no other significant category cost increases. The additional staffing has improved onboarding of new clients, account management of clients, IT process improvements and sales / marketing efforts. The full benefits of these changes are beginning to materialize particularly in the existing customer experience. The Company works to maintain a balance between new hires and new client contracts.

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

Depreciation of computer software license and property and equipment is determined on a straight-line basis over their expected useful lives. Amortization of the intangible assets, the costs associated with our mobile app began amortizing. In the third quarter our amortization of our web compatibility, web browser enhancements will begin amortizing. No other major IT projects are currently planned.

Transactions with Related Parties and Shareholders

During the year ended December 31, 2017, the company entered into a related party transaction whereby a shareholder of the company issued a loan to the company in the amount of \$60,000. The loan is unsecured and payable in ten equal payments of \$6,000 and interest of 8% on the remaining balance due on the 15th of each month, ending August 15, 2018. The loan is fully paid as at September 30, 2018.

On November 1st, 2017 the Company borrowed \$300,000 from a shareholder of the Company to assist with working capital, relating to technology projects. The loan bears interest at 8% and is repayable over forty-eight months of equal principal payments of \$6,250 plus interest. Principal payments commenced December 1st, 2017. At September 30, 2018 the current portion of the unamortized fee was \$3,063 and the non-current portion was \$6,380. The balance outstanding as at September 30, 2018 is \$237,500 (2017 – Nil).

As noted in the acquisition update financing for the cash portion of the purchase price was arranged by way of a secured loan from an arm's length shareholder in the aggregate amount of \$1,750,000. The loan bears interest at a rate of four percent (4%) per annum and matures on the date that is one (1) year, plus one (1) day from the date of issuance. Interest accrues monthly and is payable at maturity.

This transaction was in the normal course of operations.

Outstanding Share Data

As at September 30, 2018, the authorized share capital of the Company consisted of an unlimited number of common shares, an unlimited number of Class A preferred shares, an unlimited number of Class B preferred shares, an unlimited number of Class C preferred shares, an unlimited number of Class D preferred shares and an unlimited number of Class E preferred shares, of which 68,219,216 common shares were issued and outstanding at September 30, 2018. The Company currently has an aggregate of 2,950,000 options under the employee stock option plan, none of which are exercisable.

Liquidity and Capital Resources

Overall cash decreased in the second quarter as a result of paying down liabilities, operating losses and our continued investment in technology enhancements. Subsequent to the end of the quarter, as noted at the beginning of this report, the Company completed the acquisition of CBA and My Benetech. This was financed from cash on hand and a loan from a strategic investor. Management has a demonstrated track record over several years of raising capital when required.

Financial Instruments and Other Instruments

As at September 30, 2018 all monies are held in cash at a major financial institution.

Plan Sponsor Funds on Deposit Arrangements

The company had \$13,843,507 in funds on deposit as at September 30, 2018 (2017 - \$6,473,621), which represented amounts received or receivable from customers to settle specific health-care claims and related costs, adjudicated on their behalf, which are payable to the providers of the health-care or other services with respect to these claims. The increase is a direct result of the acquisition of CBA/ MBT as

NexgenRx Inc.

As at and for the three and nine months ended September 30, 2018

they too maintain customer deposits. Both the asset and an equal corresponding liability have been recorded on the balance sheet this year in recognition of increasing focus by customers and to provide greater transparency on the asset / liability flows of the Company. The increase is due to consolidation of the funds from the acquired companies.

Critical Accounting Estimates

The compilation of financial results requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant areas that require the use of judgment are the valuation of common share purchase warrants, valuation of convertible debentures, valuation of notes payable to shareholders, valuation of stock compensation. Actual results could differ from these estimates. These estimates are reviewed periodically, and as adjustments become necessary, they are reported in earnings in the period in which they become known.

Significant accounting judgments and estimation uncertainties

The Company makes estimates and assumptions concerning the future that will, by definition, seldom equal actual results. The following are estimates and judgments applied by management that most significantly impact the interim financial statements. These significant estimates and judgments have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities.

Property and equipment – estimated useful lives

Management estimates the useful lives of property and equipment based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for depreciation of property and equipment for any period are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company's property and equipment in the future.

Valuation of stock-based compensation and warrants issued

Valuation of stock-based compensation and warrants require management to make estimates regarding the inputs for option pricing models, such as expected share price volatility. Actual results could differ from these estimates. These estimates are considered for each new grant of stock options or warrants.

Additional information

Additional information related to NexgenRx Inc., including material change reports, press releases and other information is available at www.sedar.com.

This discussion includes certain statements that may be deemed "forward-looking statements". All statements in this discussion other than statements of historical facts, that address future acquisitions and events or developments that the Company expects are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements.